Posted on January 6, 2010 by Sitemaster
Recent reports have addressed the following issues related to prostate cancer:
- How many biopsy cores is the right number?
- How “open” surgeons have adapted to laparoscopic surgery
- Hypoxia, the tumor environment, and how it affects treatment
- Gefitinib + radiation therapy in intermediate- and high-risk prostate cancer
- Fractures, prostate cancer, and androgen deprivation … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: ADT, androgen deprivation therapy, biopsy, fractures, gefitinib, hypoxia, Iressa, microenvironment, radical prostatectomy, tumor | Leave a comment »
Posted on May 23, 2009 by Sitemaster
Today’s news reports focus on four items:
- Development of aggressive prostate cancer from a single cell and tumor
- Prostate size and risk for positive surgical margins
- Quality of urinary function after different types of surgery
- Gefitinib as a single agent in treatment of CRPC … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: CRPC, development, gefitinib, origin, positive surgical margins, prostate size, surgery, urinary function | Leave a comment »
Posted on May 5, 2009 by Sitemaster
We are returning to “normal” today with the standard “news reports.” Today’s items deal with:
- Evolving biomarkers and new tests and their future application
- MRI in diagnosis, staging, and prognosis of prostate cancer
- Intraprostatic injection of LHRH agonists and antagonists: is it viable?
- Gefitinib in HRPC: no evident impact on quality of life … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: agonist, antagonist, biomarkers, gefitinib, Iressa, LHRH, magnetic resonance imaging, MRI | 2 Comments »
Posted on January 21, 2009 by Sitemaster
Today’s news includes information on:
- The use of markers for prognosis following first-line treatment for localized prostate cancer
- Results of a Phase II trial of neoadjuvant docetaxel + gefitinib prior to radical prostatectomy
- Results of a Phase III trial of gabapentin in management of ADT-related “hot flashes”
- MRI-directed HIFU in the treatment of localized prostate cancer … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: docetaxel, doubling time, gabapentin, gefitinib, HIFU, hot flashes, PSA velocity | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 